Fate Therapeutics(FATE) Stock Price Today

US Stock MarketDetailed Quotes

Fate Therapeutics (FATE)

Watchlist

1.090
-0.030-2.68%

Close Dec 16 16:00 ET

125.73MMarket Cap-0.82P/E (TTM)

FATE Stock Chart

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

FATE Orderflow

Unit: --

FATE Orderflow Trend

IntradayDayWeekMonth

No Data

Fate Therapeutics (FATE) News

Wedbush Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsDec 9 09:31 ET · Ratings
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
GlobeNewswireDec 8 08:00 ET
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Fate TherapeuticsNov 25 00:00 ET
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
TipRanksNov 17 22:55 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TipRanksNov 17 02:30 ET · Ratings
Navigating Data Privacy Challenges: Fate Therapeutics' Battle With Regulatory Compliance and Business Risks
TipRanksNov 16 01:00 ET

Fate Therapeutics (FATE) Stock Forum

HailTheApocalypse

Dec 15 22:39

Share Your Profit/Loss

Comment allez vous

Oct 27 22:01

$Fate Therapeutics (FATE.US)$
what happned??

This_Guy

Oct 27 03:20

$Fate Therapeutics (FATE.US)$
Fate Therapeutics (NASDAQ: FATE) reported updated Phase 1 data for off-the-shelf CAR T product FT819 in 10 treatment-refractory moderate-to-severe systemic lupus erythematosus (SLE) patients as of a Sept 25, 2025 data cut.
Key findings: single-dose FT819 produced rapid CD19+ B-cell depletion, immune remodeling toward a naïve B-cell repertoire, durable clinical responses including two complete renal responses (CRR) at 6 months and one patient in steroid-free DORIS at...